• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Bupathi discusses JAVELIN Bladder 100 trial of maintenance avelumab

Video

Manojkumar Bupathi, MD, MS, a medical oncologist at Rocky Mountain Cancer Centers, highlights the significance of the phase 3 JAVELIN Bladder 100 trial, in which patients with unresectable locally advanced or metastatic urothelial cancer who did not have disease progression with first-line chemotherapy were randomized to best supportive care (BSC) with or without maintenance avelumab (Bavencio).

The FDA approved avelumab in this setting based on the JAVELIN Bladder 100 results, which showed a median overall survival of 21.4 months with avelumab plus BSC compared with 14.3 months with BSC alone. This 7.1-month benefit translated to a 31% reduction in the risk of death (HR, 0.69; 95% CI, 0.56-0.86; P <.001).

Related Videos
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Gary D. Steinberg, MD, an expert on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Video 2 - "Exploring Treatments for BCG-Unresponsive Intermediate-High Risk NMIBC"
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Video 1 "Unmet Needs & Standard of Care for Intermediate-High Risk NMIBC"
Related Content
© 2024 MJH Life Sciences

All rights reserved.